Daniel P O'Brien1,2,3, Deborah Friedman1, Andrew Hughes1, Aaron Walton1, Eugene Athan1. 1. Department of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia. 2. Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia. 3. Manson Unit, Médecins Sans Frontières, London, UK.
Abstract
BACKGROUND: Antibiotics are the recommended first-line treatment for Mycobacterium ulcerans disease. Antibiotic toxicity is common in Australian patients, yet antibiotic complication rates and their risk factors have not been determined. AIM: To determine the incidence rate and risk factors for antibiotic toxicity in Australian patients treated for M. ulcerans disease. METHODS: An analysis of severe antibiotic complications was performed using data from a prospective cohort of M. ulcerans cases managed at Barwon Health from 1 January 1998 to 30 June 2016. A severe antibiotic complication was defined as an antibiotic adverse event that required its cessation. Antibiotic complication rates and their associations were assessed using a Poisson regression model. RESULTS: A total of 337 patients was included; 184 (54.6%) males and median age 57 years (interquartile range (IQR) 36-73 years). Median antibiotic treatment duration was 56 days (IQR 49-76 days). Seventy-five (22.2%) patients experienced severe antibiotic complications after a median 28 days (IQR 17-45 days) at a rate of 141.53 per 100 person-years (95% confidence interval (CI) 112.86-177.47). Eleven (14.7%) patients required hospitalisation. Compared with rifampicin/clarithromycin combinations, severe complication rates were not increased for rifampicin/ciprofloxacin (rate ratio (RR) 1.49, 95% CI 0.89-2.50, P = 0.13) or rifampicin/moxifloxacin (RR 2.54, 95% CI 0.76-8.50, P = 0.13) combinations, but were significantly increased for 'other' combinations (RR 2.53, 95% CI 1.13-5.68, P = 0.03). In a multivariable analysis, severe complication rates were significantly increased with reduced estimated glomerular filtration rates (EGFR) (adjusted rate ratio (aRR) 2.65, 95% CI 1.24-5.65 for EGFR 60-89 mL/min and aRR 1.31, 95% CI 0.49-3.53 for EGFR 0-59 mL/min compared with EGFR ≥90 mL/min, P < 0.01) and female gender (aRR 2.15, 95% CI 1.38-3.30, P < 0.01). CONCLUSIONS: Severe antibiotic complications during M. ulcerans treatment are high with increased rates independently associated with reduced renal function and female gender.
BACKGROUND: Antibiotics are the recommended first-line treatment for Mycobacterium ulcerans disease. Antibiotic toxicity is common in Australian patients, yet antibiotic complication rates and their risk factors have not been determined. AIM: To determine the incidence rate and risk factors for antibiotic toxicity in Australian patients treated for M. ulcerans disease. METHODS: An analysis of severe antibiotic complications was performed using data from a prospective cohort of M. ulcerans cases managed at Barwon Health from 1 January 1998 to 30 June 2016. A severe antibiotic complication was defined as an antibiotic adverse event that required its cessation. Antibiotic complication rates and their associations were assessed using a Poisson regression model. RESULTS: A total of 337 patients was included; 184 (54.6%) males and median age 57 years (interquartile range (IQR) 36-73 years). Median antibiotic treatment duration was 56 days (IQR 49-76 days). Seventy-five (22.2%) patients experienced severe antibiotic complications after a median 28 days (IQR 17-45 days) at a rate of 141.53 per 100 person-years (95% confidence interval (CI) 112.86-177.47). Eleven (14.7%) patients required hospitalisation. Compared with rifampicin/clarithromycin combinations, severe complication rates were not increased for rifampicin/ciprofloxacin (rate ratio (RR) 1.49, 95% CI 0.89-2.50, P = 0.13) or rifampicin/moxifloxacin (RR 2.54, 95% CI 0.76-8.50, P = 0.13) combinations, but were significantly increased for 'other' combinations (RR 2.53, 95% CI 1.13-5.68, P = 0.03). In a multivariable analysis, severe complication rates were significantly increased with reduced estimated glomerular filtration rates (EGFR) (adjusted rate ratio (aRR) 2.65, 95% CI 1.24-5.65 for EGFR 60-89 mL/min and aRR 1.31, 95% CI 0.49-3.53 for EGFR 0-59 mL/min compared with EGFR ≥90 mL/min, P < 0.01) and female gender (aRR 2.15, 95% CI 1.38-3.30, P < 0.01). CONCLUSIONS: Severe antibiotic complications during M. ulcerans treatment are high with increased rates independently associated with reduced renal function and female gender.
Authors: Oliver Komm; Deepak V Almeida; Paul J Converse; Till F Omansen; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2021-08-30 Impact factor: 5.191
Authors: Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra Journal: Expert Rev Clin Pharmacol Date: 2020-04-20 Impact factor: 4.108
Authors: Daniel P O'Brien; N Deborah Friedman; Anthony McDonald; Peter Callan; Andrew Hughes; Aaron Walton; Eugene Athan Journal: PLoS Negl Trop Dis Date: 2018-03-19
Authors: Paul J Converse; Deepak V Almeida; Rokeya Tasneen; Vikram Saini; Sandeep Tyagi; Nicole C Ammerman; Si-Yang Li; Nicole M Anders; Michelle A Rudek; Jacques H Grosset; Eric L Nuermberger Journal: PLoS Negl Trop Dis Date: 2018-08-13
Authors: Richard O Phillips; Jérôme Robert; Kabiru Mohamed Abass; William Thompson; Fred Stephen Sarfo; Tuah Wilson; Godfred Sarpong; Thierry Gateau; Annick Chauty; Raymond Omollo; Michael Ochieng Otieno; Thaddaeus W Egondi; Edwin O Ampadu; Didier Agossadou; Estelle Marion; Line Ganlonon; Mark Wansbrough-Jones; Jacques Grosset; John M Macdonald; Terry Treadwell; Paul Saunderson; Albert Paintsil; Linda Lehman; Michael Frimpong; Nanaa Francisca Sarpong; Raoul Saizonou; Alexandre Tiendrebeogo; Sally-Ann Ohene; Ymkje Stienstra; Kingsley B Asiedu; Tjip S van der Werf Journal: Lancet Date: 2020-03-12 Impact factor: 79.321